Showing 1851-1860 of 2038 results for "".
- Kala Pharmaceuticals Announces Preferred Position for Eysuvis on Cignahttps://modernod.com/news/kala-pharmaceuticals-announces-preferred-position-for-eysuvis-on-cigna/2478977/Kala Pharmaceuticals announced that Cigna has added Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a preferred brand on its commercial formulary, effective May 15, 2021. “We are pleased to announce the addition of Eysuvis to Cigna’s preferred formulary, reflecting a signifi
- Graybug Vision Reports Preliminary Topline Results from Phase 2b ALTISSIMO Trialhttps://modernod.com/news/graybug-vision-reports-preliminary-topline-results-from-phase-2b-altissimo-trial/2478951/Graybug Vision provided preliminary topline data from the 12-month treatment phase of its phase 2b ALTISSIMO trial of GB-102 for the treatment of wet age-related macular degeneration (AMD), Graybug’s proprietary microparticle depot formulation of sunitinib malate injected intravitreally. T
- Retinal Therapeutics Development Company Oxular Completes $37 Million (£27 million) Financinghttps://modernod.com/news/retinal-therapeutics-development-company-oxular-completes-37-million-27-million-financing/2478922/Oxular announced that it has completed a $37 million (£27 million) to fund planned further clinical development of its lead asset, OXU-001, for the treatment of diabetic macular edema (DME), as well as accelerating development of its early-product pipeline. The financing was led by Forbion
- Allergan Launches Refresh Digital Lubricant Eye Dropshttps://modernod.com/news/abbvie-launches-refresh-digital-lubricant-eye-drops/2478901/Allergan announced the over-the-counter (OTC) launch of Refresh Digital, a new lubricant eye drop formulated to specifically relieve dryness and irritation that may occur from prolonged screen time. Refresh Digital features proprietary HydroCell technology that supports all three layers of the te
- Kala Pharmaceuticals Announces Eysuvis Now Covered by Express Scriptshttps://modernod.com/news/kala-pharmaceuticals-announces-eysuvis-now-covered-by-express-scripts/2478871/Kala Pharmaceuticals announced that pharmacy benefit manager Express Scripts has added Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% to its National Preferred, Basic and High Performance Formularies, effective February 5, 2021. Eysuvis is the first and only prescription therapy appr
- Gemini Therapeutics Debuts as Publicly Traded Company Focused on Age-Related Macular Degenerationhttps://modernod.com/news/gemini-therapeutics-debuts-as-publicly-traded-company-focused-on-age-related-macular-degeneration/2478841/Gemini Therapeutics announced the completion of its business combination with FS Development Corp., a special purpose acquisition company (SPAC) sponsored by Foresite Capital. Gemini Therapeutics, the resulting combined company, will commence trading its shares today on the Nasdaq Global Market u
- NeuroVision Imaging Receives Funding From the ADDF to Develop Biomarkers to Diagnose Alzheimer’s and Related Dementiashttps://modernod.com/news/neurovision-imaging-receives-funding-from-the-addf-to-develop-biomarkers-to-diagnose-alzheimers-and-related-dementias/2478823/NeuroVision Imaging announced it has received an investment from the Alzheimer’s Drug Discovery Foundation (ADDF) to support developing reliable, affordable biomarker tests for Alzheimer’s disease and other forms of dementia and neurodegenerative disorders. “Many of the existing diagnostic
- Ocular Therapeutix Presents Interim Topline Data from the Phase 1 Clinical Trial of OTX-TIC in Patients With Glaucomahttps://modernod.com/news/ocular-therapeutix-presents-interim-topline-data-from-the-phase-1-clinical-trial-of-otx-tic-in-patients-with-glaucoma/2478784/Ocular Therapeutix announced plans to present data on OTX-TIC, a travoprost intracameral implant for the treatment of patients with primary open angle glaucoma or ocular hypertension, at the Glaucoma 360 New Horizons Forum being held virtually on January 30. As part of the event, Michael Goldstei
- SIFI Launches Dry Eye Disease Device Synfohttps://modernod.com/news/sifi-launches-dry-eye-disease-synfo/2478726/SIFI announced the launch of Synfo, a novel medical device for dry eye disease. The new hypotonic formulation is a synergistic blend of two polymers—sodium hyaluronate and xanthan gum—and two osmoprotectants, betaine and glycine. In addition to moisturizing and lubricating, Synfo is design
- Nicox’s Partner Ocumension Therapeutics Initiates Zerviate Phase 3 Clinical Trial in Chinahttps://modernod.com/news/nicoxs-partner-ocumension-therapeutics-initiates-zerviate-phase-3-clinical-trial-in-china/2478704/Nicox SA announced that its partner, Ocumension Therapeutics, has initiated a phase 3 clinical trial in China with Zerviate, the first and only topical ocular formulation of the anti